GlassScriptPhysician profile
Michael J Schina
NPI 1003120213
$4,356.93
in general payments reported to CMS, 2019-2025
23 companies · $436 in 2025
The $436 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $705 · 2021: $808 · 2022: $652 · 2023: $415 · 2024: $801 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,651.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,241.59 | 2019-2025 | Relistor, Trulance |
| Collegium Pharmaceutical, INC. | $671.12 | 2019-2025 | Xtampza, Belbuca |
| Scilex Pharmaceuticals INC. | $388.90 | 2022-2025 | Ztlido |
| Forte Bio-Pharma LLC | $265.36 | 2020-2022 | |
| Daiichi Sankyo INC. | $106.14 | 2019 | |
| Valinor Pharma, LLC | $89.91 | 2023-2025 | Movantik |
| Arbor Pharmaceuticals, INC. | $68.91 | 2020-2021 | |
| Biodelivery Sciences International, INC. | $65.84 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $63.57 | 2022-2023 | Lyvispah |
| Depuy Synthes Sales INC. | $47.52 | 2023 | Orthovisc |
| Averitas Pharma INC. | $38.52 | 2024 | Qutenza |
| Protega Pharmaceutials INC | $36.64 | 2023 | Roxybond |
| Redhill Biopharma INC. | $35.49 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $34.50 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $28.70 | 2022-2023 | Seglentis |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $26.43 | 2025 | Gel-One Cross-Linked Hyaluronate |
| Zyla Life Sciences, INC. | $23.46 | 2019 | |
| Avanos Medical | $22.96 | 2022 | |
| Si-Bone, INC. | $22.44 | 2019 | |
| Grt US Holding, INC. | $21.81 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $19.65 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.47 | 2019 | |
| Kaleo, INC. | $18.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.